Between market rejections, cautionary ARM statements about the regulatory landscape, investment headwinds and fragmented manufacturer and R&D hubs, European biotechs have been facing a myriad of challenges in the commercialisation of ATMPs over the past few years.
Despite this, Europe receives broadsides of breakthroughs and opportunities, from major clinical milestones, developments in regulatory consideration and the realities of the impact these therapies can and will have on patients across Europe’s varied states.
Join us as a panel of experts discusses challenges in developing, launching and commercialising ATMPs in Europe. The panel of industry leaders will also share insights into which specific requirements have to be met to ensure the progress of European cell and gene therapy.
WHAT TO EXPECT
Part 1: The panel addresses key challenges associated with the uptake of advanced therapies in Europe, including:
What’s holding back development in Europe?
What infrastructure do we need for ATMPs in Europe?
How do we boost approval, market and patient access?
What’s next for the conversation?
Part 2: The panel answers audience questions with an interactive Q&A.
MEET THE PANEL
Biotech Entrepreneur with Heart for Cell & Gene
Professor Matthias Schönermark
Owner & Managing Director
SKC Beratungsgesellschaft mbH
Lee Buckler, SVP Advanced Therapies, Blood Centers of America, Advanced Therapies Network, reflects on two decades of working within the advanced therapies industry as Phacilitate celebrates 20 years of operating in the field.